CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Rating of “Moderate Buy” by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.5625.

Several equities research analysts have issued reports on the stock. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 target price (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research note on Friday. Finally, Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th.

CAMP4 Therapeutics Stock Down 8.1%

Shares of CAMP4 Therapeutics stock opened at $5.00 on Tuesday. The stock’s fifty day moving average is $4.08 and its two-hundred day moving average is $4.32. CAMP4 Therapeutics has a 52 week low of $1.41 and a 52 week high of $7.75. The company has a market capitalization of $313.75 million, a PE ratio of -2.16 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, research analysts anticipate that CAMP4 Therapeutics will post -0.84 earnings per share for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Richard A. Young purchased 16,378 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director owned 186,388 shares of the company’s stock, valued at $307,540.20. This represents a 9.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders acquired 36,031 shares of company stock valued at $59,451. 21.69% of the stock is currently owned by corporate insiders.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bridgeway Capital Management LLC purchased a new stake in CAMP4 Therapeutics in the second quarter worth about $36,000. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics during the 4th quarter valued at about $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $78,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.